CHK(CHK)
CHK
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $11.35B | $11.74B | $11.86B |
| Low | $11.35B | $11.74B | $11.86B |
| High | $11.35B | $11.74B | $11.86B |
| EBITDA Avg | $4.28B | $4.43B | $4.47B |
| Low | $4.28B | $4.43B | $4.47B |
| High | $4.28B | $4.43B | $4.47B |
| EBIT Avg | $1.90B | $1.96B | $1.98B |
| Low | $1.90B | $1.96B | $1.98B |
| High | $1.90B | $1.96B | $1.98B |
| Net Income Avg | $1.90B | $1.72B | $2.76B |
| Low | $370M | $1.72B | $2.76B |
| High | $2.45B | $1.72B | $2.76B |
| EPS Avg | $7.72 | $7.17 | $11.47 |
| Low | $1.54 | $7.17 | $11.47 |
| High | $10.20 | $7.17 | $11.47 |
| Analysts (Rev / EPS) | 3 / 6 | 1 / 2 | 1 / 3 |
| Metric | Q3 2026 | Q4 2026 |
|---|---|---|
| Revenue Avg | $2.80B | $2.89B |
| Low | $2.80B | $2.89B |
| High | $2.80B | $2.89B |
| EBITDA Avg | $1.05B | $1.09B |
| Low | $1.05B | $1.09B |
| High | $1.05B | $1.09B |
| EBIT Avg | $467M | $482M |
| Low | $467M | $482M |
| High | $467M | $482M |
| Net Income Avg | $470M | $649M |
| Low | $470M | $649M |
| High | $470M | $649M |
| EPS Avg | $1.95 | $2.70 |
| Low | $1.95 | $2.70 |
| High | $1.95 | $2.70 |
| Analysts (Rev / EPS) | 4 / 4 | 5 / 4 |